After finishing at $14.04 in the prior trading day, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $13.08, down -6.84%. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 3793291 shares were traded. NRIX stock price reached its highest trading level at $14.78 during the session, while it also had its lowest trading level at $13.05.
Ratios:
Our goal is to gain a better understanding of NRIX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.12.
On March 09, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $20.
On February 28, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $25.Oppenheimer initiated its Outperform rating on February 28, 2023, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 ’24 when van Houte Hans sold 6,812 shares for $10.02 per share. The transaction valued at 68,223 led to the insider holds 68,333 shares of the business.
Hansen Gwenn sold 2,334 shares of NRIX for $18,649 on Jan 30 ’24. The Chief Scientific Officer now owns 36,402 shares after completing the transaction at $7.99 per share. On Jan 30 ’24, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 1,760 shares for $7.99 each. As a result, the insider received 14,063 and left with 17,427 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 640.27M and an Enterprise Value of 382.97M. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.31 while its Price-to-Book (P/B) ratio in mrq is 3.18. Its current Enterprise Value per Revenue stands at 4.97 whereas that against EBITDA is -2.71.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $16.11, while it has fallen to a 52-week low of $4.22. The 50-Day Moving Average of the stock is 10.30, while the 200-Day Moving Average is calculated to be 8.87.
Shares Statistics:
The stock has traded on average 808.92K shares per day over the past 3-months and 1.21M shares per day over the last 10 days, according to various share statistics. A total of 48.72M shares are outstanding, with a floating share count of 45.03M. Insiders hold about 7.90% of the company’s shares, while institutions hold 89.13% stake in the company. Shares short for NRIX as of Feb 29, 2024 were 6.85M with a Short Ratio of 8.46, compared to 7.29M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.00% and a Short% of Float of 14.33%.
Earnings Estimates
Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.8 for the current quarter, with a high estimate of -$0.64 and a low estimate of -$0.95, while EPS last year was -$0.75. The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.65 and low estimates of -$1.
Analysts are recommending an EPS of between -$2.03 and -$3.8 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$3.11, with 10 analysts recommending between -$1.3 and -$4.94.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $146M, while the lowest revenue estimate was $50.35M, resulting in an average revenue estimate of $69.15M. In the same quarter a year ago, actual revenue was $76.99M, down -10.20% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $74.89M in the next fiscal year. The high estimate is $201M and the low estimate is $33.4M. The average revenue growth estimate for next year is up 8.30% from the average revenue estimate for this year.
